Oneview Healthcare (ASX:ONE) - CEO, James Fitter (left) and President & Founder, Mark McCloskey (right)
CEO, James Fitter (left) and President & Founder, Mark McCloskey (right)
Source: Silicon Republic
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Oneview Healthcare (ONE) confirms the signing of Northern Health as its first Cloud Start customer in Australia
  • Oneview’s Cloud Start product enables patients to communicate with their clinicians in a covid-safe manner, using its Oneview Care Experience Platform
  • The company’s Cloud Start product will be deployed to Northern Health’s recently completed $162.3 million Stage 2 Inpatient Unit Expansion Project, which became operational in May 2021
  • Oneview Healthcare was up 6.02 per cent, trading at 44 cents at 11:50 am AEST

Oneview Healthcare (ONE) has confirmed the signing of Northern Health as its first Cloud Start customer in Australia.

Northern Health is a provider of acute, maternity and specialist services in Melbourne’s outer north through its four main campuses, Northern Hospital Epping, Broadmeadows Hospital, Bundoora Centre, and Craigieburn Centre, in the area’s fast-growing northern growth corridor.

Oneview’s Cloud Start product will be deployed to Northern Health’s recently completed $162.3 million Stage 2 Inpatient Unit Expansion Project, which became operational in May 2021.

Oneview’s Cloud Start product enables patients to communication with their clinicians in a covid-safe manner, using its Oneview Care Experience Platform.

The platform unifies a facility’s systems, content and services into one digital platform, with dedicated devices at the point of care. In doing so, the company says it delivers more control for patients and their families, more time for care teams, and less complexity for executives and IT teams.

The project is expected to go live in the third quarter of 2021.

Oneview Healthcare is up 4.82 per cent, trading at 43.5 cents at 11:30 am AEST.

ONE by the numbers
More From The Market Online

ResMed spikes on robust results and global growth spurt

ResMed shares have climbed following the release of the company's strong Third Quarter FY2024 results.

PharmAust CEO’s sayanora triggers stock plunge

Clinical-stage biotechnology company, PharmAust shares plunged 24 per cent so this morning, following the resignation of…

Recce wins safety board approval to dose 4g in R327 UTI infusion trial

Recce Pharma will dose patients with 4g of its R327 intravenous solution to treat UTIs in…

Emyria locks in $2.3M to progress MDMA research – with Chair adding $0.3M

WA-based and ASX-listed Emyria is seeking to further research using MDMA to treat PTSD. The chair…